Factor 8 Gene Roctavian denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for factor 8 gene roctavian are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Roctavian (valoctocogene roxaparvovec) — Duplicate Therapy

Roctavian is an FDA-approved adeno-associated virus (AAV) gene therapy for adults with severe hemophilia A. It is administered as a single intravenous infusion intended to enable the patient's liver cells to produce Factor VIII on their own, potentially eliminating or drastically reducing the need for ongoing factor replacement. Cigna's "duplicate therapy" denial means its system flagged that the patient is already receiving — or has recently received — another Factor VIII product, and classified Roctavian as redundant.

## Why This Denial Is Appealable

This denial reflects a fundamental misclassification of what Roctavian is. Roctavian is not a replacement infusion that competes with ongoing prophylaxis on a dose-for-dose basis; it is a one-time gene therapy designed to make ongoing replacement therapy unnecessary. Classifying it as "duplicate" to standard Factor VIII concentrate is clinically incorrect. The appropriate framing is that Roctavian is the definitive intervention and ongoing Factor VIII infusions are the bridge therapy that Roctavian is intended to replace. A well-structured appeal that explains this distinction — ideally with a prescriber letter and the FDA label — should resolve the misclassification.

## Federal Appeal Framework

• Internal appeal: File with Cigna within 180 days of the denial. Request a clinical peer-to-peer review if available; having your hematologist speak directly with Cigna's medical director often resolves misclassification denials quickly.
• External review (ACA §2719): If Cigna upholds the denial internally, you have approximately four months to request independent external review. Given the novelty of gene therapy, external reviewers will apply the FDA-approved labeling and recognized hemophilia treatment guidelines.
• ERISA §503: Employer plan members have the right to see the exact criteria and guidelines Cigna applied, and to submit a response.
• Expedited review: If delaying Roctavian would cause serious clinical harm (e.g., imminent high-risk bleed, inability to maintain prophylaxis), request expedited processing.

## Documentation to Gather

1. FDA prescribing label for Roctavian — specifically the indication, mechanism of action, and the section describing the relationship between gene therapy and ongoing factor replacement. 2. Prescriber letter distinguishing gene therapy from replacement therapy — your hematologist should explain that Roctavian and Factor VIII concentrate are not duplicate therapies but rather sequential treatments with distinct mechanisms. 3. Current treatment regimen documentation — pharmacy records showing ongoing Factor VIII use, which provides context that Roctavian is intended to replace, not add to, that regimen. 4. Hemophilia treatment center (HTC) evaluation — documentation that the patient has been evaluated at an HTC and is a candidate for gene therapy per the treating team's assessment. 5. Cigna's coverage policy — download Cigna's current medical/coverage policy for gene therapy and for Factor VIII products, and identify the specific duplicate-therapy language.

## Criteria-Mapping Structure

Your appeal letter should directly rebut the duplicate-therapy classification: - Column A: The specific duplicate-therapy criterion from Cigna's policy or denial letter. - Column B: The clinical and regulatory distinction between Roctavian (gene therapy, one-time) and Factor VIII concentrate (replacement therapy, ongoing) — citing the FDA label and prescriber letter.

Close by requesting that Cigna re-adjudicate the claim under its gene therapy policy rather than its Factor VIII replacement policy.